Sepsis Remains a Global Health Emergency
Sepsis remains one of the most serious global health challenges. According to the World Health Organization (WHO), an estimated 48.9 million cases of sepsis and 11 million sepsis-related deaths were reported globally in 2017, accounting for approximately one-fifth of all deaths worldwide.
Sepsis can affect people of all ages and can develop as a complication of infections acquired in the community or healthcare settings. Because its progression can be rapid and its clinical presentation may overlap with other conditions, timely recognition and appropriate treatment are essential.
For healthcare systems, this means that preparedness for sepsis cannot rely on a single diagnostic pathway. It requires the ability to identify infection early, understand its potential source, and obtain relevant information to support treatment decisions.
World Sepsis Day 2026: Invest in Sepsis – Save Lives
September 13 is World Sepsis Day, a global reminder of the continuing impact of sepsis and the need for stronger prevention, recognition, treatment, and preparedness.
The theme for World Sepsis Day 2026 — “Invest in Sepsis – Save Lives” — highlights the importance of investment across the sepsis care pathway, including healthcare systems, healthcare professionals, research and innovation, and communities.
Diagnostics are an important part of this investment. Being prepared to identify pathogens and antimicrobial resistance can help healthcare professionals make more informed decisions when infection is suspected.
The 2026 SSC Guideline: Early When Indicated, Narrow When Possible
The 2026 Surviving Sepsis Campaign (SSC) guidelines emphasize a risk-stratified approach to antimicrobial therapy.
For adults with possible, probable, or definite septic shock, or with probable or definite sepsis without shock, antimicrobial therapy should be started immediately, ideally within one hour of recognition. For patients with possible sepsis without shock, the guidelines recommend a rapid investigation and, when infection remains a concern, antimicrobial therapy within three hours of initial suspicion.
At the same time, antimicrobial therapy should not remain unnecessarily broad. When microbiological information becomes available, treatment should be reassessed and de-escalated when appropriate.
This highlights a fundamental diagnostic need: timely information matters not only for starting treatment, but also for refining it.
From Infection to Sepsis: One Condition, Multiple Infection Pathways
Sepsis does not originate from a single type of infection. Respiratory, urinary, bloodstream, gastrointestinal, and other infections can all contribute to its development. This is where diagnostic readiness becomes important.
Instead of relying on a single-pathogen approach, multiplex pathogen detection can provide broader information from one diagnostic workflow, helping identify multiple clinically relevant pathogens associated with different infection syndromes.
At the same time, antimicrobial resistance (AMR) detection adds another important layer of information. Knowing not only what may be causing an infection, but also whether key resistance markers are present, can support more informed antimicrobial decision-making.
Together, multiplex pathogen detection and AMR detection provide a more comprehensive approach to infection assessment — from “What is causing the infection?” to “What treatment options may need to be considered?”
Supporting Multiple Infection Pathways with Diagnostic Solutions
To support different infection scenarios, Macro & Micro-Test provides multiplex molecular testing solutions covering a range of clinical pathways, including:
- 32x-Respiratory infections
- 34x-Urinary tract infections
- 22x-Gastrointestinal infections
- 15x-Bloodstream infections
- 22x-Encephalitis & meningitis
- C. difficile Infection-Toxin A/B gene
- AMR: KPC, NDM, OXA-48, OXA-23, VIM, and IMP; SA&MRSA…
These solutions are designed to help laboratories and healthcare settings address different infection pathways while obtaining broader pathogen information within a single testing workflow.
AIO800 Automation: Bringing Diagnostic Readiness into the Workflow
Diagnostic readiness is not only about what can be detected. It is also about how efficiently testing can be performed. The Eudemon™ AIO800 Fully Automated Molecular System integrates key steps from sample processing and nucleic acid extraction to amplification and result interpretation in a Sample-to-Answer workflow.
By combining automation with multiplex molecular testing, AIO800 can help simplify complex testing workflows and support more efficient pathogen detection across different infection scenarios.
Investing in Diagnostic Readiness
Sepsis can develop from many different infections, and no single diagnostic test can answer every clinical question.
A stronger approach is to build diagnostic readiness across multiple infection pathways — combining multiplex pathogen detection, AMR detection, and automated Sample-to-Answer workflows.
On World Sepsis Day 2026, “Invest in Sepsis – Save Lives” is also a reminder that investment in timely and comprehensive diagnostics is an investment in better preparedness for infection and sepsis.
Multiple Infection Pathways.
Multiplex Pathogen Detection.
AMR Detection.
AIO800 Automation.
Invest in Sepsis. Save Lives.
Post time: Sep-11-2026